Precision Medicine · us
Must rare-disease therapies be one drug per patient? Study uses shared genetic markers to broaden ASO applicability
Patients with different disease-causing mutations may still be able to share the same precision drug. An SCN2A study proposes matching therapies by genetic markers, but genetic eligibility remains a long way from proven treatment efficacy.
Developing a drug for one patient with a rare disease may change a family's life. But if development must start again for every mutation, more patients may still be left waiting for treatment. A study of SCN2A-related neurodevelopmental disorders proposes that patients with different disease-causing mutations could potentially use the same antisense oligonucleotide (ASO), provided they share suitable genetic markers.
The study was published on November 5 in The American Journal of Human Genetics, and Rady Children’s Health released an overview on November 11. Starting with two ASOs originally developed for individual patients, the team examined whether genomic information could help match existing drug candidates to more patients, reducing the need to design each one from scratch.
The key is distinguishing the disease-causing copy of the gene from the normal copy. The ASOs in the study target a sequence containing common genetic variation in SCN2A RNA that has not yet completed splicing, selectively reducing expression of the disease-causing copy while preserving the normal copy. These shared genetic markers can be inherited together along a segment of DNA, forming a “haplotype.” The drug therefore does not need to directly recognize each patient's unique disease-causing mutation.
Shared markers alone, however, are not enough. The team used whole-genome sequencing and haplotype analysis to confirm whether the marker and the disease-causing variant were on the same copy of the gene, and whether the normal copy had a sequence that allowed it to be distinguished. The combination of two haplotypes is called a “diplotype.” Among 21 patients with SCN2A-related neurodevelopmental disorders, 10, or approximately 48%, had diplotypes that met the matching criteria for the two existing ASOs. This does not mean that all 10 had received treatment or experienced improvement.
The study also used data from the 1000 Genomes Project to identify SCN2A markers shared across broader populations, combining computational analysis with validation in cells to evaluate candidate ASOs. Together, four haplotype-specific ASOs provided potential genetic coverage of 76.2% of the participants analyzed. This figure describes opportunities for sequence matching; it cannot be interpreted as a treatment success rate or directly applied to all patients with SCN2A-related disorders.
This approach remains constrained by disease mechanisms. The study focused on SCN2A variants involving gain of function, or a combination of gain and loss of function. Whether reducing expression of the disease-causing copy could improve the condition must be assessed individually. Although the paper mentions evidence of safety and efficacy from the original individual-patient trials, the expanded matching analysis did not demonstrate that other patients would also benefit, much less establish efficacy across a patient population or long-term safety.
The next step outlined by the study is to establish a set of ASOs in advance and then match them to patients using their sequencing results, rather than starting over each time. This could allow more people to benefit from advances in personalized treatment development, but the selectivity, safety, and clinical effects of each drug still require supporting evidence. The authors also disclosed that three study participants were Illumina employees and shareholders, and that three researchers had filed patent applications related to the work.